• NewcelX entered a binding term sheet to sell its worldwide Mazindol portfolio to REA Holdings.
• Upfront consideration totals $500,000, comprising $30,000 cash and shares representing 9.4% of REA's fully diluted equity following closing.
• Potential milestone payments reach $55 million, with tiered royalties of 2%-8% on annual global net sales of Mazindol products.
• REA would assume future development and commercialization costs, allowing the seller to focus on its cell-therapy pipeline for Type 1 diabetes.
• The transaction remains subject to definitive documentation and customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869477) on November 04, 2026, and is solely responsible for the information contained therein.